Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Novartis Domestic Sales Up 6% Despite Drop in Diovan
February 8, 2012
- All-Case PMS for Chugai’s Tarceva for NSCLC Lifted
February 8, 2012
- Janssen Files NDA for Anti-HIV Agent Edurant in Japan
February 8, 2012
- JCR Hopes to Build Delivery Network, Boost Product Promotion in Collaboration with Medipal: Chairman Ashida
February 7, 2012
- DSP President Tada Says Steady Shift to Latuda Seen in US
February 7, 2012
- JCR to Push Joint Development with GSK, Including New Biopharmaceuticals
February 7, 2012
- Apr-Dec Sales Rise 7.4% due to Vidaza: Nippon Shinyaku
February 7, 2012
- Apr-Dec Sales Up 1.9% Driven by Artz: Kaken
February 7, 2012
- Astellas to Establish New Global Human Resources Committee on April 1
February 7, 2012
- Takeda Announces US Launch of Combination Hypertension Treatment Edarbyclor
February 7, 2012
- Sanofi-aventis Initiates ALOHA 2 Study of Lantus Plus DPP-4 Inhibitors for Type 2 Diabetes
February 7, 2012
- Pfizer Japan to Launch 2 Generic APIs on Feb 8, Total 18 APIs
February 6, 2012
- OncoTherapy to Jointly Initiate PIII Study for OCV-C01 with Otsuka
February 6, 2012
- US, European Pharmaceutical Companies Supported by Steady Japan Business Growth
February 6, 2012
- Lipitor Generics Have Over 6% of Negative Impact: Astellas
February 6, 2012
- Pfizer Highly Rated for Pharmacist Support: Nextit Research Survey
February 6, 2012
- Mr Tsuchiya of Eisai Disapproves Virtual Permission of Off-label Use of Generics Not Approved for the Same Indications as Their Original Drugs
February 6, 2012
- Chugai Pharmaceutical Dec 2011 Sales Decline After Earthquake Despite Steady Sales Abroad
February 6, 2012
- Number of MRs Breaks 60,000; Could Become Major Topic in Light of Strained Healthcare Finances
February 6, 2012
- Eisai Says Impact from Generic Versions of Aricept Insignificant
February 3, 2012
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…